In-Depth Notes on HIV and AIDS

Overview of HIV and AIDS

  • HIV (Human Immunodeficiency Virus) is the infectious agent, while AIDS (Acquired Immunodeficiency Syndrome) is the disease caused by the virus.
  • HIV/AIDS presents an opportunity to explore the interplay between the immune system and a viral pathogen.

Historical Context

  • HIV first recognized as a clinical entity in 1981.
  • The virus has led to over 30 million deaths globally, with 37 million currently living with HIV.

Global Statistics (2012)

  • Total infected: 35.3 million (Estimates range: 32.2 - 38.8 million).
  • New infections: 2.3 million (Estimates range: 1.9 - 2.7 million).
  • Sub-Saharan Africa holds the highest prevalence, with 25 million infected individuals.
Regional HIV/AIDS Statistics
  • Breakdown of HIV prevalence within regions:
    • Sub-Saharan Africa: 25.0 million
    • North America and Western Europe: Lower prevalence rates
  • Variability in prevalence rates highlights differing epidemic situations.

Origins of HIV

  • HIV originated from cross-species transmission from African monkeys to humans.
  • Two predominant types are:
    • HIV-1: Most common globally (98% of cases).
    • HIV-2: Mostly found in West Africa and generally less transmissible.
HIV-1 Subtypes
  • Subtypes M, N, O, and P; subtype M accounts for over 90% of global infections.
  • Emergence linked to various environmental and host factors in human populations.

Transmission of HIV

  • Transmission requires a breach in physical barriers through:
    • Micro-abrasions during sexual intercourse.
    • Use of contaminated needles and blood products.
  • Probability of Transmission: Various sites (e.g., vaginal, rectal) have differing probabilities of leading to HIV infection:
    • Female genital (vagina): 1 in 200 - 1 in 2,000
    • Male genital (rectum): 1 in 20 - 1 in 300

HIV Characteristics

  • Structure: Enveloped RNA virus that utilizes reverse transcription to integrate into host DNA.
  • Infection Mechanism: Targets CD4 T cells, weakening the immune response over time.

Immune Response to HIV

  • The initial immune response involves CTLs (Cytotoxic T Lymphocytes) and antibodies, which can suppress the virus temporarily but ultimately fail.
  • Key Factors Affecting Immune Control:
    • Loss of CD4 T cells due to HIV infection.
    • Development of antigenic variants that escape immune recognition.

Disease Progression

  • As HIV damages CD4 T cells, it leads to a severe immunodeficiency state, known as AIDS, characterized by opportunistic infections.
  • Typical symptoms of AIDS arise when CD4 counts fall below critical thresholds.

Opportunities and Challenges in Vaccine Development

  • Developing an effective HIV vaccine remains a challenge due to the high mutation rates and antigenic variability of the virus.
  • Strategies for vaccine development include the study of broadly neutralizing antibodies that can target multiple strains of HIV.

Genetic Resistance to HIV

  • Certain genetic variations, such as the delta 32 mutation in the CCR5 gene, confer resistance to HIV infection, albeit rarely.
  • Long-term non-progressors exhibit slow disease progression, maintaining low levels of viral load.

Current Status and Future Directions

  • Cases of functionally cured patients (e.g., "Berlin Patient") provide avenues for future research on potential cures.
  • Continued efforts are underway in vaccine research, focusing on eliciting broad immune responses effective against diverse HIV strains.

Conclusion

  • HIV/AIDS remains a significant global health challenge, necessitating ongoing research for effective treatments and prevention strategies.